Clinical benefits of PD-1 inhibitors in specific subgroups of patients with advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis of phase 3 randomized clinical trials
暂无分享,去创建一个
Feng Wang | Wenkang Wang | Feng Wang | Yao Lu | Yao Lu
[1] Huiyan Jiang,et al. 69O First-line serplulimab versus placebo in combination with chemotherapy in PD-L1-positive oesophageal squamous cell carcinoma (ASTRUM-007): A randomised, double-blind, multicentre phase III study , 2022, Annals of Oncology.
[2] E. Raymond,et al. LBA-1 RATIONALE-306: Randomized, global, placebo-controlled, double-blind phase 3 study of tislelizumab plus chemotherapy versus chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC) , 2022, Annals of Oncology.
[3] Sung-Bae Kim,et al. Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] L. Kong,et al. Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial , 2022, BMJ.
[5] Qi Zhang,et al. Dynamic profiling of immune microenvironment during pancreatic cancer development suggests early intervention and combination strategy of immunotherapy , 2022, EBioMedicine.
[6] Qi Li,et al. Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial. , 2022, Cancer cell.
[7] J. Ajani,et al. Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma. , 2022, The New England journal of medicine.
[8] P. Ascierto,et al. Pembrolizumab for previously treated advanced anal squamous cell carcinoma: results from the non-randomised, multicohort, multicentre, phase 2 KEYNOTE-158 study. , 2022, The lancet. Gastroenterology & hepatology.
[9] M. Zhang,et al. Efficacy and optimal combination timing of chemotherapy combined with PD-1 inhibitor in advanced cervical cancer: a multicenter retrospective cohort study , 2022, Annals of translational medicine.
[10] Feng Wang,et al. PD-1 Inhibitor Plus Chemotherapy Versus Chemotherapy as First-line Treatment for Advanced Esophageal Cancer: A Systematic Review and Meta-Analysis , 2021, Journal of immunotherapy.
[11] X. Chen,et al. Clinical and biomarker analyses of sintilimab versus chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma: a randomized, open-label phase 2 study (ORIENT-2) , 2021, Nature communications.
[12] Jie He,et al. Esophageal cancer: Epidemiology, risk factors and screening , 2021, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.
[13] Ying Cheng,et al. Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial. , 2021, JAMA.
[14] Sung-Bae Kim,et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study , 2021, The Lancet.
[15] Menglin Xu,et al. The efficacy and safety of antibodies targeting PD-1 for treatment in advanced esophageal cancer: A systematic review and meta-analysis , 2021, Translational oncology.
[16] A. Jemal,et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.
[17] A. Mansfield,et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial , 2021, The Lancet.
[18] R. Scolyer,et al. Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumours: a guide to immunohistochemistry implementation and interpretation. , 2020, Pathology.
[19] T. Watson,et al. The Underfunding of Esophageal Cancer Research. , 2020, The Annals of thoracic surgery.
[20] K. Emancipator. Keytruda and PD-L1: a Real-World Example of Co-development of a Drug with a Predictive Biomarker , 2020, The AAPS Journal.
[21] Sung-Bae Kim,et al. Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] Li Zhou,et al. The Impact of Liver Metastasis on Anti-PD-1 Monoclonal Antibody Monotherapy in Advanced Melanoma: Analysis of Five Clinical Studies , 2020, Frontiers in Oncology.
[23] L. Zitvogel,et al. Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors , 2020, Nature Reviews Clinical Oncology.
[24] Erratum: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. , 2020, CA: a cancer journal for clinicians.
[25] Y. Ba,et al. Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study. , 2020, The Lancet. Oncology.
[26] Sung-Bae Kim,et al. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. , 2019, The Lancet. Oncology.
[27] K. Syrigos,et al. Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. , 2019, The New England journal of medicine.
[28] S. Thrumurthy,et al. Oesophageal cancer: risks, prevention, and diagnosis , 2019, BMJ.
[29] Qiong Wu,et al. Effect of region on the Outcome of Patients Receiving PD-1/PD-L1 Inhibitors for Advanced Cancer. , 2019, International immunopharmacology.
[30] R. Greil,et al. Baseline Absolute Lymphocyte Count and ECOG Performance Score Are Associated with Survival in Advanced Non-Small Cell Lung Cancer Undergoing PD-1/PD-L1 Blockade , 2019, Journal of clinical medicine.
[31] Feiran Wang,et al. Correlation between patients’ age and cancer immunotherapy efficacy , 2019, Oncoimmunology.
[32] Yongmei Song,et al. PD-L1 expression and its clinicopathological correlation in advanced esophageal squamous cell carcinoma in a Chinese population , 2019, Diagnostic Pathology.
[33] R. Mehta,et al. Pembrolizumab for the treatment of patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction cancer: an evidence-based review of place in therapy , 2018, OncoTargets and therapy.
[34] A. Jemal,et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.
[35] B. King-Kallimanis,et al. Age-related differences in patient-reported outcomes in patients with advanced lung cancer receiving anti-PD-1/PD-L1 therapy. , 2018, Seminars in oncology.
[36] R. Gelber,et al. Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis. , 2018, The Lancet. Oncology.
[37] Bing-he Xu,et al. Safety, Activity, and Biomarkers of SHR-1210, an Anti-PD-1 Antibody, for Patients with Advanced Esophageal Carcinoma , 2018, Clinical Cancer Research.
[38] M. Delgado-Rodríguez,et al. Systematic review and meta-analysis. , 2017, Medicina intensiva.
[39] Sheng-Jie Yu,et al. Esophageal cancer: Risk factors, genetic association, and treatment. , 2016, Asian journal of surgery.
[40] V. Servois,et al. Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[41] Z. Miedzybrodzka,et al. Gefitinib and EGFR Gene Copy Number Aberrations in Esophageal Cancer. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] Razelle Kurzrock,et al. Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate , 2017, Clinical Cancer Research.
[43] F. Hirsch,et al. PD‐L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD‐L1 IHC Assay Comparison Project , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[44] Ronald D. Vale,et al. T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition , 2016, Science.
[45] Y. Shentu,et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. , 2016, The New England journal of medicine.
[46] S. Klein,et al. Sex differences in immune responses , 2016, Nature Reviews Immunology.
[47] D. Stănculeanu,et al. Development of new immunotherapy treatments in different cancer types , 2016, Journal of medicine and life.
[48] J. Birk,et al. Trends in esophageal cancer survival in United States adults from 1973 to 2009: A SEER database analysis , 2016, Journal of gastroenterology and hepatology.
[49] Y. Shentu,et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial , 2016, The Lancet.
[50] Y. Liu,et al. Paclitaxel plus cisplatin vs. 5-fluorouracil plus cisplatin as first-line treatment for patients with advanced squamous cell esophageal cancer. , 2016, American journal of cancer research.
[51] Razelle Kurzrock,et al. PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy , 2015, Molecular Cancer Therapeutics.
[52] D. Cunningham,et al. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. , 2014, The Lancet. Oncology.
[53] N. Sugimoto,et al. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[54] S. Park,et al. A randomized phase II study of biweekly irinotecan monotherapy or a combination of irinotecan plus 5-fluorouracil/leucovorin (mFOLFIRI) in patients with metastatic gastric adenocarcinoma refractory to or progressive after first-line chemotherapy , 2013, Cancer Chemotherapy and Pharmacology.
[55] David C. Smith,et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.
[56] J. Geddes,et al. What is a randomised controlled trial? , 2009, Epidemiologia e Psichiatria Sociale.
[57] Haidong Dong,et al. Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion , 2002, Nature Medicine.
[58] G. Zhu,et al. Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion , 2002, Nature Medicine.
[59] S. Rosen,et al. Cisplatin and 5‐fluorouracil in the primary management of squamous esophageal cancer , 1987, Cancer.